Vertex Pharmaceutical’s New Hepatitis C Drug May Have Negative Effects | Hepatitis Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Menu Search
Previous

Hepatitis C and Porphyria Cutanea Tarda

Back to News Homepage
Next

OraSure Technologies' OraQuick is the Only Federally Approved Rapid Hepatitis C Test

Vertex Pharmaceutical’s New Hepatitis C Drug May Have Negative Effects

The Editors at Hepatitis Central
July 29, 2013

Print this page

In a study for the drug VX-135, patients developed increased levels of liver enzymes. The FDA has put a partial clinical hold on the drug until they can fully study their toxicity concerns.

Vertex: FDA Puts Partial Hold on Study of Hepatitis C Drug

By Kristin Jones

Vertex Pharmaceuticals Inc. (VRTX) said the U.S. Food and Drug Administration has put a partial clinical hold on a mid-stage study of its experimental hepatitis C treatment VX-135 because of toxicity concerns.

Vertex shares fell 9.1% to $79.66 in after-hours trading.

The drug developer said the hold affects the 200-milligram dose of VX-135, a drug known as a nucleotide polymerase inhibitor, or “nuke,” which is designed to combat hepatitis C infection inside liver cells. Vertex joins Bristol-Myers Squibb Co. (BMY) and Idenix Pharmaceuticals Inc. (IDIX) in having to halt certain trials of nuke drugs because of toxicity concerns.

Continue reading this entire article:
http://online.wsj.com/article/BT-CO-20130725-718983.html

1 Comment
Share
Share
Previous

Hepatitis C and Porphyria Cutanea Tarda

Back to News Homepage
Next

OraSure Technologies' OraQuick is the Only Federally Approved Rapid Hepatitis C Test

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.